BeiGene Expands Capabilities to Serve More Patients, Cements Global Oncology Leader Status with Opening of U.S. Biologics Manufacturing and R&D Center in N.J.
BeiGene today opened its flagship U.S. biologics and manufacturing site in Hopewell, N.J. – greatly expanding our differentiated manufacturing, research and clinical development capabilities that are driving our global oncology leadership
The new state-of-the-art facility – located in the Princeton West Innovation Campus– increases our biologics manufacturing capacity for our growing portfolio and also supports our global geographic expansion. Additionally, it reinforces our differentiated oncology research capabilities and strengthens our diversified global supply chain.
The site features approximately 400,000 square feet of dedicated commercial-stage biologics manufacturing space, with the ability to expand over time. With unique internal end-to-end manufacturing capabilities for biologics production that create cost, speed and technology advantages, as well as supply chain resiliency, the new facility will support efficient global distribution at scale, allowing us to get our medicines to more patients around the world.
Discovering, developing innovative treatments
We’ve built one of the most prolific oncology pipelines in the industry – with assets addressing 80 percent of all cancers, including innovative modalities such as antibody drug conjugates (ADCs) and monoclonal antibodies – and this new facility creates flexibility to scale production and clinical development of our medicines today and in the future. It also will:
- Enhance our supply chain diversity and capacity for our large-molecule products while also providing capacity for small-molecule production in the future;
- Serve as a hub for our global, integrated clinical development supply chain for investigational medicines; and
- Support our current and future clinical operations, helping us reach more clinical trial sites and enabling more programs executed with the highest quality and efficiency.
Our $800 million investment in the facility is the culmination of a three-year project to expand our physical footprint in the U.S., extend our global reach, and create approximately 130 high-tech skilled jobs by 2025, supporting New Jersey’s dynamic biotech sector.
Fulfilling our vision
The new site will provide many gains for our company, the state and local community.
More importantly, today’s opening represents a major step toward fulfilling our vision of creating innovative medicines that are more affordable and accessible to more cancer patients around the world.
“This is a great day for BeiGene, the State of New Jersey, Hopewell Township and, most importantly, for patients,” said Co-Founder, Chairman and CEO John V. Oyler. “This new facility means that we can produce more medicines for more patients with some of the most challenging unmet medical needs.”
John was joined at the opening ceremony by other company leaders, state and local officials, including Governor Phil Murphy, and patient advocacy and community partners.
Founded in 2010, BeiGene is a leading global oncology company that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. Our growing global team of more than 10,000 colleagues spanning five continents is united by the same focus on “patients first” – our core value – that guided the founding of our company and the creation of the new site we are all proud to see opened today.